spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product LinesConnecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product Lines

Searching News Database:  hormone replacement therapy 

 HSMN NewsFeed - 11 Dec 2020
BAVENCIO(R) (avelumab) Receives Positive CHMP Opinion for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 9 Apr 2020
EMD Serono and Pfizer Receive US FDA Breakthrough Therapy Designation and Submit Application for BAVENCIO(R) for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 13 Mar 2020
EMD Serono and Pfizer Provide Update on Phase III JAVELIN Head and Neck 100 Study
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Nov 2018
Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on Avelumab in Platinum-Resistant/Refractory Ovarian Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 Apr 2018
Juniper Pharmaceuticals Licenses Intravaginal Ring (IVR) Platform to Daré Bioscience
Biopharmaceutical Drug Delivery Licensing
 HSMN NewsFeed - 29 Dec 2017
Mylan Adds to U.S. Women's Healthcare Portfolio With FDA Approval of First Generic for Estrace(R) Cream
Biopharmaceuticals Generics FDA Product Launch
 HSMN NewsFeed - 21 Sep 2017
European Commission Approves Bavencio (avelumab) for Metastatic Merkel Cell Carcinoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 21 Jul 2017
EMA's CHMP Issues Positive Opinion for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 9 May 2017
FDA Grants BAVENCIO(R) (avelumab) Approval for a Common Type of Advanced Bladder Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 24 Mar 2017
FDA Grants Approval for BAVENCIO(R) (avelumab), the First Immunotherapy Approved for Metastatic Merkel Cell Carcinoma
Biopharmaceuticals Oncology FDA Product Launch
 HSMN NewsFeed - 26 Jul 2016
AbbVie Receives U.S. FDA Approval of Once-Daily VIEKIRA XR(TM) (dasabuvir, ombitasvir, paritaprevir and ritonavir) for the Treatment of Genotype 1 Chronic Hepatitis C
Biopharmaceuticals FDA
 HSMN NewsFeed - 24 Nov 2015
European Commission Approves Reconciliation of Indications for nivolumab Under the Opdivo(R) European Marketing Authorization Application
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 24 Nov 2015
Bristol-Myers Squibb Announces U.S. Food and Drug Administration Approval for Opdivo (nivolumab) as a Single Agent for the Treatment of Patients with Previously Untreated BRAF Wild-Type Advanced Melanoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 1 Oct 2015
Bristol-Myers Squibb Receives Approval from the U.S. Food and Drug Administration for the Opdivo (nivolumab) + Yervoy (ipilimumab) Regimen in BRAF V600 Wild-Type Unresectable or Metastatic Melanoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 24 Apr 2015
Bristol-Myers Squibb Receives Positive CHMP Opinion in the European Union for Opdivo (nivolumab) for the Treatment of Advanced Melanoma in Both First-Line and Previously Treated Patients
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 26 Mar 2014
Pfizer Achieves Primary Endpoint With Phase 3B Top-Line Results Of GENOTROPIN(R) In Very Young Children Born Small For Gestational Age
Biopharmaceuticals
 HSMN NewsFeed - 21 Aug 2013
Novo Nordisk receives U.S. FDA clearance for the insulin injection device NovoPen Echo(R)
Biopharmaceuticals Devices Drug Delivery FDA
 HSMN NewsFeed - 12 Apr 2013
Veracyte Announces Appointment of Shelly D. Guyer as Chief Financial Officer
Diagnostics Personnel
 HSMN NewsFeed - 22 May 2012
FDA Approves Levemir(R) for Expanded Use in Children Two to Five Years of Age with Type 1 Diabetes
Biopharmaceuticals Endocrinology FDA
 HSMN NewsFeed - 27 Apr 2012
Novo Nordisk plans 15 percent expansion of U.S. work force in 2012
Biopharmaceuticals
 HSMN NewsFeed - 2 Apr 2012
FDA Approves Levemir(R) Pregnancy Category Change for Women with Diabetes
Biopharmaceuticals Endocrinology FDA
 HSMN NewsFeed - 21 Apr 2011
Novo Nordisk Announces U.S. Launch of NovoTwist(R) for Use with Levemir(R) FlexPen(R), NovoLog(R) FlexPen(R) and Victoza(R) Pen Devices
Devices Drug Delivery Endocrinology
 HSMN NewsFeed - 8 Apr 2011
Antares Pharma Announces FDA Acceptance of Anturol(R) NDA for Filing
Biopharmaceuticals Urology
 HSMN NewsFeed - 31 Jan 2011
GATTEX(R) (teduglutide) Meets Primary Efficacy Endpoint in Phase 3 Pivotal Study in Patients with Adult Short Bowel Syndrome
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 28 Sep 2010
Published Study Shows PEM Sensitivity Equivalent to Breast MRI
Devices Radiology
 HSMN NewsFeed - 4 Mar 2010
Watson Announces Agreement to Acquire U.S. Rights to Columbia Laboratories' CRINONE(R) Progesterone Gel Product Line
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 3 Mar 2010
Novo Nordisk Receives FDA Approval for Norditropin(R) FlexPro(R) for Growth Hormone Treatment
Biopharmaceuticals Devices Drug Delivery FDA
 HSMN NewsFeed - 26 Jan 2010
Novo Nordisk's Victoza(R) Receives FDA Approval for Adults With Type 2 Diabetes
Biopharmaceuticals Endocrinology FDA
 HSMN NewsFeed - 29 May 2009
Novo Nordisk: New study directly comparing insulin delivery devices shows that Next Generation FlexPen has a significantly lower injection force than SoloStar and KwikPen
Biopharmaceuticals Drug Delivery Endocrinology
 HSMN NewsFeed - 2 Apr 2009
Update on FDA Advisory Committee Meeting on Liraglutide for the Treatment of Type 2 Diabetes
Biopharmaceuticals Endocrinology FDA
 HSMN NewsFeed - 13 May 2008
FDA Approves NOVO NORDISK's NovoSeven(R) RT (Coagulation Factor VIIa [Recombinant] Room Temperature Stable) for Hemophilia Patients With Inhibitors
Biopharmaceuticals FDA
 HSMN NewsFeed - 27 Mar 2008
Pieris Raises EUR 25 M (US$ 38 M) in Series B Financing Round
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 23 Jan 2008
The American Association of Clinical Endocrinologists (AACE) Strongly Supports the FDA in Its Concerns Regarding the Marketing and Use of So-Called Bio-Identical Hormones
Biopharmaceuticals. FDA
 HSMN NewsFeed - 17 Dec 2007
Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 15 Oct 2007
Sepracor Announces Senior Management Appointments as Part of Commercial Re-Organization
Biopharmaceuticals Personnel
 HSMN NewsFeed - 21 Sep 2007
Norditropin(R) Approved for Treatment of Children with Short Stature Associated with Turner Syndrome
Biopharmaceuticals FDA
 HSMN NewsFeed - 19 Sep 2007
PREOS(R) Granted U.S. Orphan Drug Status for Treatment of Hypoparathyroidism
Biopharmaceuticals FDA
 HSMN NewsFeed - 5 Jul 2007
Peer Reviewed Journal Article Indicates Repros' Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 Jun 2007
New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir(R)
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 13 Jun 2007
Bradley Pharmaceuticals Announces Launch of Elestrin(TM)
Biopharmaceuticals
 HSMN NewsFeed - 1 Jun 2007
FDA Approves Norditropin(R)for Treatment of Short Stature Associated with a Rare Genetic Disorder
Biopharmaceuticals FDA
 HSMN NewsFeed - 11 Apr 2007
Cell Therapeutics, Inc. (CTI) Announces XYOTAX(TM) Has Fast Track Designation for Women With Advanced Lung Cancer Who Are Performance Status 2 (PS2)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 10 Jan 2007
Cell Therapeutics, Inc. (CTI) Files for Special Protocol Assessment (SPA) With FDA for XYOTAX Lung Cancer Trial in Women
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Jan 2007
Antares ATD(TM) Formulation Enters Phase III Study
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 19 Oct 2006
PharmaNova Grants Exclusive U.S. License to Depomed for Extended Release Gabapentin Use in Hot Flashes
Biopharmaceuticals Licensing
 HSMN NewsFeed - 18 Oct 2006
Depomed Obtains Exclusive License to Gabapentin Use in Hot Flashes
Biopharmaceuticals Licensing
 HSMN NewsFeed - 17 Oct 2006
NovoSeven(R) Becomes First and Only Recombinant Therapy for Treatment of Rare, Life-Threatening Bleeding Disorder
Biopharmaceuticals FDA
 HSMN NewsFeed - 6 Oct 2006
New River Pharmaceuticals Inc. Receives Approvable Letter for NRP104
Biopharmaceuticals FDA
 HSMN NewsFeed - 7 Sep 2006
SurModics and X-Cell Medical Collaborate on Drug Eluting Stent Development
Devices Interventional Cardiology Licensing
 HSMN NewsFeed - 16 May 2006
X-Cell Medical Completes Enrollment for Clinical Trial of ETHOS II Estradiol Eluting Stent
Devices Interventional Cardiology
Return to NewsFeed  

 Additional items found! 56

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 56 additional stories matching:
hormone replacement therapy
(Password required)
FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.


RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!